A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

BACKGROUND: Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and glycopyrronium. Previous studies have compared glycopyrronium with open-label tiotropium. In the GLOW5 study, we compare gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Kenneth R, Beeh, Kai-Michael, Beier, Jutta, Bateman, Eric D, D’Urzo, Anthony, Nutbrown, Robert, Henley, Michelle, Chen, Hungta, Overend, Tim, D’Andrea, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907130/
https://www.ncbi.nlm.nih.gov/pubmed/24438744
http://dx.doi.org/10.1186/1471-2466-14-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907130/
https://www.ncbi.nlm.nih.gov/pubmed/24438744
http://dx.doi.org/10.1186/1471-2466-14-4

Ejemplares similares